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Abstract 
Background 
The Biochemistry and Haematology Outcome Model (BHOM) relies on the results from routine index 
blood tests to predict the patient risk of death. We aimed to externally validate the BHOM model. 
Method 
We considered all emergency adult medical patients who were discharged from Northern 
Lincolnshire and Goole (NLAG) hospital in 2014. We compared patient characteristics between NLAG 
(the validation sample) and the hospital where BHOM was developed. We evaluated the predictive 
performance, according to discriminative ability (with a concordance statistic, c), and calibration 
(agreement between observed and predicted risk). 
Result 
There were 29 834 emergency discharges of which 24 696 (83%) had complete data. In comparison 
with the development sample, the NLAG sample was similar in age, blood test results, but 
experienced a lower mortality (4.7% vs 8.7%). When applied to NLAG, the BHOM model had good 
discrimination (c-statistic 0.83 [95% CI 0.823 - 0.842]). Calibration was good overall, although the 
BHOM model overpredicted for lowest (<5%, observed = 229,predicted =286) and highest (≥50%, 
observed = 31, predicted = 49)  risk groups, even after recalibrating for the differences in baseline 
risk of death. 
Conclusion 
Differences in patient case-mix profile and baseline risk of death need to be considered before the 
BHOM model can be used in another hospital. After re-calibrating for the baseline difference in risk 
the BHOM model had good discrimination but less adequate calibration. 
Keywords:  Critical Care; Emergency Medicine; Biochemistry & metabolism 
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Introduction 
Statistically derived risk equations are widely used to support healthcare professionals in the 
research, audit and delivery of healthcare. Examples of risk equations include Acute Physiology and 
Chronic Health Evaluation (APACHE),1 Mortality Probability Model (MPM),2 and for more examples 
see.3 Typically the risk equations are developed by randomly splitting the data into two parts – 
"training" and "testing". This approach, known as internal validation,4 has been criticised because (a) 
the subsequent model performance statistics are optimistic and (b) typically, the use of the risk 
equation is beyond the settings where the equation was first developed and internal validation does 
not give any indication about the performance of the model in another setting. The use of external 
validation, where the model is tested using data from another setting, is now seen as an important 
step in model development. 4–8 
The Biochemistry and Haematology Outcome Model (BHOM) was developed by researchers at 
Portsmouth Hospital NHS Trust based on routinely collected biochemistry and haematology blood 
test results along with basic demographic information for 9 497 adults discharged from a medical 
speciality hospital during one year (January 2001 – December 2001).  A major advantage of the 
BHOM model is that the covariates are clinically meaningful, collected as part of the process of care 
and these data are available within a few hours of the patient admission. The BHOM model was 
internally validated and found to have good discrimination (c-statistics 0.757 to 0.779) and good 
calibration (non-significant p-values from the Hosemer-Lemeshow deciles of risk table) 9 -10. 
Nonetheless the BHOM model has not been externally validated – an important step before it can 
used outside of the hospital in which it was developed. 
We aimed to externally validate the BHOM model, by considering its calibration and discrimination 
in a cohort of patients discharged from another hospital following an acute admission. 
 4 
 
Methods 
Setting & data for external validation 
Our cohort of emergency admissions is from the Northern Lincolnshire and Goole NHS Foundation 
Trust (NLAG) in England. All 24 696 adults (age≥16 years) emergency patients discharged during the 
year 2014 (1 January 2014 to 31 December 2014) were included. For each admission we obtained 
the patients age, gender (male/female), discharge status (alive/dead) and index blood test results 
used in the BHOM model from the hospital computer system. The covariates set was:- age on 
admission (years), gender (female=0/male=1), albumin (g/L), creatinine (µmol/L), haemoglobin, 
potassium (mmol/L), sodium (mmol/L), white cell count (109 cells/L), urea (mmol/L), and ratio of urea 
(mmol/L) and creatinine (µmol/L). We also considered records which had no missing data (24 696/29 
834 (83%)), as did here.9 We did not consider elective patients because the intended use of the 
BHOM model in NLAG was for acute medical patients. 
The BHOM Model 
The BHOM risk equation is shown below:- 
𝑙𝑜𝑔 (
𝑅
1 − 𝑅
) = −10.192 − (0.013 × 𝑔𝑒𝑛𝑑𝑒𝑟) + (5.712 × 𝑚𝑜𝑑𝑒 𝑜𝑓 𝑎𝑑𝑚𝑖𝑠𝑠𝑖𝑜𝑛)
+ (0.053 × 𝑎𝑔𝑒 𝑜𝑛 𝑎𝑑𝑚𝑖𝑠𝑠𝑖𝑜𝑛) + (0.018 × 𝑢𝑟𝑒𝑎) − (0.001 × 𝑠𝑜𝑑𝑖𝑢𝑚)
− (0.101 × 𝑝𝑜𝑡𝑎𝑠𝑠𝑖𝑢𝑚) − (0.047 × 𝑎𝑙𝑏𝑢𝑚𝑖𝑛) − (0.037 × ℎ𝑎𝑒𝑚𝑜𝑔𝑙𝑜𝑏𝑖𝑛)
+ (0.067 × 𝑤ℎ𝑖𝑡𝑒 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡) + (0.001 × 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒) + (2.744
× 𝑢𝑟𝑒𝑎/𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒) 
Where R is risk of death in hospital and the variables gender and mode of admission are coded 
female=0, male=1, elective=0, and emergency=1, respectively. The other covariates are continuous 
values based on routine blood test results. 
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Statistical analyses 
We followed a previously proposed framework for the external validation of clinical prediction 
models.6 There are two key steps: 
1. To determine the relatedness of the patients in the model development sample with the 
patients in the external validation sample. This preliminary step helps to determine the 
extent to which the model is being validated in a patient population that is not materially 
dissimilar to the development sample. 
2. To assess the performance of the model on the external validation sample by determining 
the model discrimination and calibration. For discrimination, we use the area under the 
receiver-operator curve (AUROC) or concordance (c)-statistic. AUROC is the probability that 
the model will predict a higher risk of death for a randomly selected patient who died, 
compared to a randomly selected patient who survived.4-5 Calibration is the relationship 
between the observed and predicted risk of death and can be usefully seen on a scatter plot 
(y-axis observed risk, x-axis predicted risk). Perfect predictions should be on the 45° line.  
The intercept (a) and slope (b) of this line gives an assessement of ‘calibration-in-the-
large’.11 At model development, a = 0 and b = 1, but at validation, calibration-in-the-large 
problems are indicated if a is not 0 and if b is more/less than 1 as this reflects problems of 
under/over prediction.5 We also use the Hosmer–Lemeshow (HL) goodness of fit test for 
calibration with degree of freedom 𝑑𝑓 = 𝑔 − 1,4 where 𝑔 is deciles of risk groups as defined 
by Prytherch et al., 2005 (see Table 2). 
Before we could apply the BHOM model we made two adjustments based on preliminary 
observations. (1) We divided the NLAG haemoglobin results by 10 to ensure they were compatible 
with units for haemoglobin in the BHOM model. (2) We noted that the mortality in NLAG is almost 
half that of Portsmouth Hospital (4.69% vs 8.7%). To correct for this difference in baseline risk we 
adjusted the constant term in the BHOM model, by trial and error (see supporting Microsoft Excel 
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file)  and selecting the value (-11.3235) which produced optimal calibration. The mean risk of death 
for NLAG from the model with the revised constant was thus similar with BHOM model 4.69% 12. 
Ethical Approval 
The study does not require ethical approval because it meets the exemption criteria ("Research 
limited to secondary use of information previously collected in the course of normal care (without 
an intention to use it for research at the time of collection), provided that the patients or service 
users are not identifiable to the research team in carrying out the research.13)" 
Results 
Cohort description 
There were 29 834 emergency discharges from during the year 2014, of which 24 696 (83%) had 
complete data. The mean age of patients was 63.1 years (SD 21.1), the female to male ratio was 1.14 
and the in-hospital mortality was 4.69% (1159/24696).  The relationship between the continuous 
covariates and mortality are shown in Figure 1 and Figure 2. 
External Validation Results 
Step 1: Relatedness of the patient samples 
The mean and SD for each continuous covariates showed no major differences between the 
development sample (Portsmouth Hospital) and external validation sample (NLAG), with the 
exception of albumin which appear to be higher in Portsmouth. 
 
Step 2: Assessing the model performance  
We applied the BHOM model to the validation sample at NLAG. The resulting c-statistic 
(discrimination) was 0.833 (95% confidence interval 0.823 to 0.843) and the calibration in-the-large 
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was 𝑎 = 0 and 𝑏 = 0.99.  Calibration plots (Figure 3), without and with re-calibration for differences 
in baseline risk showed systematic over prediction which still persisted in the higher risk (risk >0.40)  
groups. 
 
The H-L deciles of risk calibration test (see table 2), after recalibrating for baseline differences, was 
statistically significant p<0.001 (X2 = 51.49, 8 df). Over prediction was evident in the lowest risk group 
(≥0% to <5%, n=16804, X2 = 10.13, 1 df), where there were 229 observed deaths compared with 286 
predicted deaths, and in the highest risk group (≥50% to <100%, n=66, X2 = 27.40, 1 df), where there 
were 31 observed deaths compared with 43 predicted deaths. Under prediction was seen in the fifth 
risk group ( ≥12.5% to <15%, n=695, X2 = 7.15, 1 df) where there were 119 observed deaths 
compared with 95 predicted deaths. 
Discussion 
The performance of the BHOM model based on internal validation was good - the discrimination (c-
statistic) for BHOM was 0.757 to 0.779 and the Hosmer-Lemeshow deciles of risk calibration 
produced no statistically significant difference between predicted and observed mortality (p>0.05). 
We undertook an external validation exercise for the BHOM model using data for emergency 
medical admissions at NLAG hospital over one year. As far as we are aware, this is the first external 
validation attempt of the BHOM model. We found that after re-calibrating for the baseline 
difference in risk between the two cohorts of patients, the BHOM model had good discrimination, 
but less adequate calibration - it over predicted for lowest (<5%, observed = 229, predicted =286) 
and highest (≥50%, observed = 31 , predicted = 49)  risk groups. 
Whilst the BHOM model has attractive features of using results from routine blood tests (without 
additional data collection) its use outside of hospital in which it was developed requires attention to 
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two key issues. (1) Consideration and, where necessary, correction for differences in baseline risk by 
adjusting the constant term in the BHOM model. (2) Investigation of predicted versus observed risk 
as seen in a calibration plots, which in our case, showed that differences persisted even after 
correcting for baseline differences in risk of death. The inadequate calibration is not readily 
explained by difference in the distribution of continuous and categorical covariates. Further work to 
consider reasons for inadequate calibration are required. There are several possible issues. (1) The 
sample sizes at NLAG are almost three times as large as Portsmouth hospital (24 696 vs 9 497). This 
would increase the risk of spuriously low p-values which are statistically significant but clinically 
insignificant. (2). The calibration deteriorates in higher (≥50%) risk groups and so the model 
predictions could be capped at this threshold. (3) The relationship between covariates and risk of 
death may be significantly different in NLAG versus a Portsmouth hospital. This could be explored 
using tests for interactions. Nonetheless it is worth emphasising that whilst these desktop 
approaches are useful and can correct for some issues in model performance, the ultimate question 
is to determine the extent to which such risk equations support clinical decision making and enhance 
safety and quality of patient care. 
Conclusion 
Differences in patient case-mix profile and baseline risk of death need to be considered before the 
BHOM model can be used in another hospital. We found that after re-calibrating for the baseline 
difference in risk between the two cohorts of patients, the BHOM model had good discrimination, 
but less adequate calibration. 
References 
1.  Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease 
classification system. Crit Care Med [Internet]. 1985 Oct [cited 2015 Feb 19];13(10):818–29. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/3928249 
 9 
 
2.  Lemeshow S, Teres D, Klar J, Avrunin JS, Gehlbach SH, Rapoport J. Mortality Probability 
Models (MPM II) based on an international cohort of intensive care unit patients. JAMA. 
1993;270(20):2478–86.  
3.  Vincent J-L, Moreno R. Clinical review: scoring systems in the critically ill. Crit Care. 
2010;14(2):207.  
4.  Steyerberg EW. Clinical Prediction Models. A practical approach to development, validation 
and updating. Springer; 2008.  
5.  Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the 
performance of prediction models: a framework for traditional and novel measures. 
Epidemiology [Internet]. 2010 Jan [cited 2014 Jul 12];21(1):128–38. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3575184&tool=pmcentrez&ren
dertype=abstract 
6.  Debray TP a., Vergouwe Y, Koffijberg H, Nieboer D, Steyerberg EW, Moons KGM. A new 
framework to enhance the interpretation of external validation studies of clinical prediction 
models. J Clin Epidemiol [Internet]. Elsevier Inc; 2014;68(3):279–89. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S0895435614002753 
7.  Collins GS, de Groot JA, Dutton S, Omar O, Shanyinde M, Tajar A, et al. External validation of 
multivariable prediction models: a systematic review of methodological conduct and 
reporting. BMC Med Res Methodol [Internet]. 2014 Jan [cited 2015 May 2];14(1):40. 
Available from: http://www.biomedcentral.com/1471-2288/14/40 
8.  van de Laar R, IntHout J, Van Gorp T, Verdonschot S, van Altena  a M, Gerestein CG, et al. 
External validation of three prognostic models for overall survival in patients with advanced-
stage epithelial ovarian cancer. Br J Cancer [Internet]. Nature Publishing Group; 
2014;110(1):42–8. Available from: http://www.nature.com/doifinder/10.1038/bjc.2013.717 
9.  Prytherch DR, Sirl JS, Schmidt P, Featherstone PI, Weaver PC, Smith GB. The use of routine 
laboratory data to predict in-hospital death in medical admissions. Resuscitation. 
2005;66(2):203–7.  
10.  Badriyah T of P. Developing Risk of Mortality and Early Warning Score Models using Routinely 
Collected Data [Internet]. University of Portsmouth; 2013. Available from: 
http://eprints.port.ac.uk/13999/1/Thesis_Tessy_Badriyah_2013.PDF 
11.  Cox DR. Two further applications of a model for binary regression. Biometrika [Internet]. 
1958 Dec 1 [cited 2015 Oct 25];45(3-4):562–5. Available from: 
http://biomet.oxfordjournals.org/content/45/3-4/562.citation 
12.  Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A calibration 
hierarchy for risk models was defined: from utopia to empirical data. J Clin Epidemiol 
[Internet]. 2016 Jan 6 [cited 2016 Apr 15]; Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26772608 
13.  NHS Health Research Authority. Governance Arrangements for Research Ethics Committees 
[Internet]. [cited 2015 Nov 20]. Available from: http://www.hra.nhs.uk/resources/research-
legislation-and-governance/governance-arrangements-for-research-ethics-committees/ 
 
  
 10 
 
 
 
Portsmouth 
Hosptial 
NLAG 
Variables Mean SD Mean SD 
Age (years) 63.3 20.8 63.1 21.1 
Albumin (g/L) 39.7 5.7 34.0 6.2 
Creatinine (µmol/L) 114.3 80.5 100.3 77.9 
Haemoglobin  13.5 2.2 12.9 2.2 
Potassium (mmol/L) 4.3 0.6 4.1 0.6 
Sodium (mmol/L) 137.8 4.4 137.0 4.8 
White cell count (10
9
 cells/L) 10.4 4.9 9.9 6.9 
Urea (mmol/L) 8.0 6.7 7.3 5.8 
Urea (mmol/L)/ Creatinine (µmol/L) 0.07 0.03 0.07 0.03 
 
Table 1: Relatedness of continuous covariates in BHOM and NLAG data sets 
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Risk group(%) No. of cases Mean predicted risk (%) Predicted Observed      X
2 
≥0 to <5 16804 1.70 286 229 10.13 
≥5 to <7.5 3023 6.16 186 209 2.25 
≥7.5 to <10 1801 8.65 156 175 3.14 
≥10 to <12.5 1090 11.13 121 125 0.07 
≥12.5 to <15 695 13.64 95 119 7.15 
≥15 to <20 651 17.17 112 113 0.01 
≥20 to <25 292 22.24 65 69 0.73 
≥25 to <33 173 28.17 49 47 0.40 
≥33 to <50 101 39.31 40 42 0.22 
≥50 to <100 66 74.90 49 31 27.40 
≥0 to <100 24696 - 1159 1159 51.49 
Table 2: Hosmer-Lemeshow deciles of risk table 
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Figure 1: Boxplot without outliers for continuous covariates with respect to patient’s discharge 
status (Alive/Died) 
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Figure 2: Scatter plots showing the observed risk of death with continuous covariates. 
NB: y-axis range changes in each plot. 
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Figure 3: Calibration plots: (A) before recalibrating the BHOM model (B) after recalibrating for differences in 
baseline risk. 
Dashed line is the ideal. Dotted line is actual. 
 

